Source:http://linkedlifedata.com/resource/pubmed/id/20933414
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
22
|
| pubmed:dateCreated |
2010-10-19
|
| pubmed:abstractText |
Design and synthesis of cis-2,6-disubstituted N-arylsulfonyl morpholines as novel ?-secretase inhibitors for the potential treatment of Alzheimer's disease (AD) is reported. Several different small alkyl groups are installed on the left-hand side to lower the CYP3A4 liability while maintaining excellent in vitro potency.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1464-3405
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6606-9
|
| pubmed:meshHeading | |
| pubmed:year |
2010
|
| pubmed:articleTitle |
Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as ?-secretase inhibitors.
|
| pubmed:affiliation |
Department of Chemical Research, Merck Research Lab., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. hongmei.li@spcorp.com
|
| pubmed:publicationType |
Journal Article
|